We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Johnson & Johnson Scraps $1.6 Billion AML Drug Pact With Argenx
Johnson & Johnson Scraps $1.6 Billion AML Drug Pact With Argenx
Johnson & Johnson (J&J) has decided to call it quits on its global collaboration and licensing agreement with Argenx, an arrangement for a blood cancer drug hashed out in late 2018 that was worth up to $1.6 billion.